Across TCGA pan-cancer cohorts, TPSB2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TPSB2 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher TPSB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TPSB2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

COAD and GBM are the cancer types where TPSB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.147	0.693	<.001	23	view →
GBM	DFS	Median	All	1.000	0.192	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TPSB2 tumor-vs-normal RNA expression · all TPSB2 data types